| Company Name: | American Medical Systems Holdings, Inc. | | Ticker Symbol: | AMMD | | | WWW Address: | www.visitams.com |
| CEO: | Mr. Anthony P. Bihl,III | | No. of Employees: | 1,221 |
| Common Issue Type: | CS | | Business Description: | The Company manufactures & markets surgical products to urologists, gynecologists & urogynecologists for erectile restoration, benign prostatic hyperplasia, male urethral stricture, urinary & fecal incontinence, menorrhagia, & pelvic organ prolapse.
|
| | | Industry Information: | HEALTH SERVICES - Medical Appliances & Equipment [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 29.98 |  0.0 | - | - | | 29.98 | 29.98 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 2,316.4 | 77.3 | 0.70 | 1.12 | 0.00 | 26.8 | 0.0 | 29.99 - 17.62 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 29.98 | $ | | PE Ratio - LTM | 26.8 | |
| Market Capitalisation | 2,316.4 | mil |
| Latest Shares Outstanding | 77.3 | mil |
| Earnings pS (EPS) | 1.12 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 432,124 | $ |
| Effective Tax Rate | 36.0 | % |
| Float | 61.4 | mil |
| Float as % of Shares Outstanding | 79.0 | % |
| Foreign Sales | 147 | mil |
| Domestic Sales | 395 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 42.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 9.90 | % |
| Gross Profit Margin | 87.4 | % |
| EBITDA Margin | 35.4 | % |
| Pre-Tax Profit Margin | 24.3 | % |
| Assets Turnover | 0.5 | % |
| Return on Assets (ROA) | 8.1 | % |
| Return on Equity (ROE) | 12.6 | % |
| Return on Capital Invested (ROCI) | 9.4 | % |
| Current Ratio | 3.9 | |
| Leverage Ratio (Assets/Equity) | 1.6 | |
| Interest Cover | 11.1 | |
| Total Debt/Equity (Gearing Ratio) | 0.34 | |
| LT Debt/Total Capital | 25.0 | % |
| Working Capital pS | 2.56 | $ |
| Cash pS | 0.35 | $ |
| Book-Value pS | 9.05 | $ |
| Tangible Book-Value pS | -0.95 | $ |
| Cash Flow pS | 1.59 | $ |
| Free Cash Flow pS | 1.45 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.31 | |
| Price/Tangible Book Ratio | -31.66 | |
| Price/Cash Flow | 18.8 | |
| Price/Free Cash Flow | 20.7 | |
| P/E as % of Industry Group | 153.0 | % |
| P/E as % of Sector Segment | 111.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 99 | 21,484 | |
| 4 Weeks | 29.99 | 29.91 | 29.90 | 0.3 | 104 | 17,853 | 267,797 |
| 13 Weeks | 29.99 | 21.02 | 21.25 | 41.1 | 145 | 32,022 | 1,889,306 |
| 26 Weeks | 29.99 | 18.16 | 19.21 | 56.1 | 153 | 20,522 | 2,503,724 |
| 52 Weeks | 29.99 | 17.62 | 22.75 | 31.8 | 111 | 14,237 | 3,530,686 |
| YTD | 29.99 | 18.16 | - | 59.0 | 156 | 21,075 | 2,465,802 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 29.97 | 29.96 | 29.79 | 23.49 | 22.34 | 0.70 | 0.90 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 12.45 | 81.9 | 3.99 |
| Income | 0.00 | 0.0 | 56.51 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -44.44 | NA | 124.56 |
| R&D | 16.49 | NA | 6.98 |
| Normalized Inc. | 12.68 | NA | 30.84 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 4.3 | 4.3 | 4.4 |
| Earnings % | 4.4 | 4.4 | 2.6 |
| EPS % | 0.0 | 0.0 | -1.8 |
| EPS $ | 0.00 | 0.00 | -0.02 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 15.46 |
| Current Ratio | 3.3 |
| Quick Ratio (Acid Test) | 2.5 |
| Liquidity Ratio (Cash) | 1.12 |
| Receivables Turnover | 5.4 |
| Average Collection Period | 67 |
| Working Capital/Equity | 24.4 |
| Working Capital pS | 2.12 |
| Cash-Flow pS | 1.60 |
| Free Cash-Flow pS | 1.38 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 4.90 |
| Financial Leverage Ratio (Assets/Equity) | 1.6 |
| Debt Ratio | 36.5 |
| Total Debt/Equity (Gearing Ratio) | 0.35 |
| LT Debt/Equity | 0.35 |
| LT Debt/Capital Invested | 34.9 |
| LT Debt/Total Liabilities | 61.1 |
| Interest Cover | 10.7 |
| Interest/Capital Invested | 1.43 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 38.25 |
| Tobin's Q Ratio | 2.21 |
| Current P/E Ratio - LTM | 26.80 |
| Enterprise Value (EV)/EBITDA | 13.85 |
| Enterprise Value (EV)/Free Cash Flow | 26.43 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -31.66 |
| Price/Book Ratio - LTM | 3.31 |
| Price/Cash Flow Ratio | 18.8 |
| Price/Free Cash Flow Ratio - LTM | 20.7 |
| Price/Sales Ratio | 4.23 |
| P/E Ratio (1 month ago) - LTM | 26.7 |
| P/E Ratio (26 weeks ago) - LTM | 18.0 |
| P/E Ratio (52 weeks ago) - LTM | 19.3 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 153.0 |
| P/E as % of Sector Segment | 111.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 26.8 |
| PER SHARE FIGURES |
| LT Debt pS | 3.06 |
| Current Liabilities pS | 0.91 |
| Tangible Book Value pS - LTM | -0.95 |
| Book Value pS - LTM | 9.05 |
| Capital Invested pS | 11.70 |
| Cash pS - LTM | 0.35 |
| Cash Flow pS - LTM | 1.59 |
| Free Cash Flow pS - LTM | 1.45 |
| Earnings pS (EPS) | 1.12 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 19.50 |
| Free Cash Flow Margin 5YEAR AVG | -24.63 |
| Net Profit Margin | 16.0 |
| Net Profit Margin - 5YEAR AVRG. | 7.5 |
| Equity Productivity | 0.81 |
| Return on Equity (ROE) | 13.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 8.1 |
| Capital Invested Productivity | 0.60 |
| Return on Capital Invested (ROCI) | 9.6 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 3.8 |
| Assets Productivity | 0.50 |
| Return on Assets (ROA) | 8.3 |
| Return on Assets (ROA) - 5YEAR AVRG. | 3.3 |
| Gross Profit Margin | 87.4 |
| Gross Profit Margin - 5YEAR AVRG. | 83.4 |
| EBITDA Margin - LTM | 35.4 |
| EBIT Margin - LTM | 26.7 |
| Pre-Tax Profit Margin | 25.1 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 14.2 |
| Effective Tax Rate | 36.0 |
| Effective Tax Rate - 5YEAR AVRG. | 25.9 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 236 |
| Revenue per Employee | 432,124 |
| Net Income per Employee | 69,331 |
| Average Collection Period | 65 |
| Receivables Turnover | 5.4 |
| Day's Inventory Turnover Ratio | 171 |
| Inventory Turnover | 2.1 |
| Inventory/Sales | 6.2 |
| Accounts Payble/Sales | 1.63 |
| Assets/Revenue | 2.00 |
| Net Working Capital Turnover | 3.33 |
| Fixed Assets Turnover | 0.66 |
| Total Assets Turnover | 0.5 |
| Revenue per $ Cash | 32.91 |
| Revenue per $ Plant | 13.10 |
| Revenue per $ Common Equity | 0.81 |
| Revenue per $ Capital Invested | 0.60 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 42.6 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 43.4 |
| Research & Devlopment (R&D) as % of Revenue | 9.8 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 9.8 |
|
|  
| | |  |  | |
| |
